Cosmetic cross-reference

Salicylamide

CAS 65-45-2

Salicylamide (CAS 65-45-2) is a Phase 2 pharmaceutical compound with 3 bioactivity targets and 166 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

166

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Salicylamide

CAS Number

65-45-2

UNII

EM8BM710ZC

InChIKey

SKZKKFZAGNVIMN-UHFFFAOYSA-N

ChEMBL ID

CHEMBL27577

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL27577 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	20728.741666666665 nM	19	-
-	IC50	40325.43666666667 nM	5	-
-	AC50	8912.5 nM	1	-

SOURCE DrugCentral 6 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Sedation complication	38	181.043	10079741
Creatinine renal clearance decreased	39	178.812	10011372
Blood calcium decreased	39	156.332	10005395
Orthostatic hypotension	39	135.843	10031127
Sedation	38	132.19	10039897
Cognitive disorder	40	128.577	10057668

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE PharmGKB 4 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

- rs9933632

Genotypes GT + TT are associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype GG.

Evidence: -; PMID 29239905

- rs6500265

Genotypes CT + TT are associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype CC.

Evidence: -; PMID 29239905

- rs9933632

Evidence: 3; PMID 1

- rs6500265

Evidence: 3; PMID 1

SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
salicylamide	9518	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Salicylamide used for in pharmaceutical contexts?

Salicylamide (CAS 65-45-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Salicylamide?

Salicylamide has 166 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Sedation complication, Creatinine renal clearance decreased, Blood calcium decreased, Orthostatic hypotension, Sedation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Salicylamide also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Salicylamide with EU status "permitted".

What clinical phase is Salicylamide in?

Salicylamide is rendered with ChEMBL max phase 2.